



*vaccines*



an Open Access Journal by MDPI

## Tumor Antigen-Based Anticancer Vaccine and Immunotherapy

Guest Editor:

**Dr. Franco M. Buonaguro**

Istituto Nazionale Tumori—IRCCS  
Fondazione Pascale, Napoli, Italy

Deadline for manuscript  
submissions:

**28 February 2025**

### Message from the Guest Editor

Anti-cancer vaccines and immunotherapies are the most recent and successful strategies against cancer. Since the early 2000s, focused target therapy has replaced non-selective cytotoxic chemotherapy, leading to significant advancements in cancer treatment. Small interfering molecules and monoclonal antibodies have effectively modulated immune responses but have limited contribution to the active immune response, which is the goal of immunotherapy. This Special Issue focuses on research activities addressing the transformation of immunologically inert tumors into immunologically reactive cancers suitable for specific control or elimination from the host immune system. We welcome manuscripts addressing critical *in vitro* and *in vivo* issues to optimize strategies, from identifying tumor-specific antigens and tumor-associated antigen epitopes to exploring immune checkpoint inhibitors.



[mdpi.com/si/208025](https://mdpi.com/si/208025)

**Special** Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)